Shares of Opthea Limited (NASDAQ:OPT - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $3.07, but opened at $3.22. Opthea shares last traded at $3.24, with a volume of 8,734 shares traded.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on the stock. HC Wainwright restated a "buy" rating and issued a $12.00 target price on shares of Opthea in a report on Friday, February 28th. Canaccord Genuity Group upgraded shares of Opthea to a "strong-buy" rating in a research note on Tuesday, December 17th.
View Our Latest Stock Analysis on OPT
Opthea Stock Performance
The business's 50-day moving average price is $4.45 and its 200-day moving average price is $4.06.
Institutional Investors Weigh In On Opthea
Hedge funds have recently modified their holdings of the business. ABC Arbitrage SA bought a new stake in shares of Opthea during the 4th quarter valued at $40,000. OLD Mission Capital LLC bought a new position in Opthea in the 4th quarter worth $42,000. Twin Lakes Capital Management LLC bought a new position in Opthea in the 3rd quarter worth $81,000. Citadel Advisors LLC bought a new position in Opthea in the 4th quarter worth $79,000. Finally, Jane Street Group LLC bought a new position in Opthea in the 3rd quarter worth $114,000. Institutional investors own 55.95% of the company's stock.
Opthea Company Profile
(
Get Free Report)
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Recommended Stories
Before you consider Opthea, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Opthea wasn't on the list.
While Opthea currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
